3 228

Cited 45 times in

Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts

Authors
 Bong Joo Park  ;  Jong-Chul Park  ;  Hideaki Taguchi  ;  Kazutaka Fukushima  ;  Suong-Hyu Hyon  ;  Kosuke Takatori 
Citation
 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol.347(2) : 401-405, 2006 
Journal Title
 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
ISSN
 0006-291X 
Issue Date
2006
MeSH
Amphotericin B/pharmacology ; Antifungal Agents/pharmacology* ; Candida/drug effects* ; Candida/growth & development ; Candida/isolation & purification ; Candidiasis/microbiology ; Catechin/analogs & derivatives* ; Catechin/pharmacology ; Dose-Response Relationship, Drug ; Echinocandins ; Fluconazole/pharmacology ; Flucytosine/pharmacology ; Humans ; Itraconazole/pharmacology ; Lipopeptides ; Lipoproteins/pharmacology ; Micafungin ; Miconazole/pharmacology ; Microbial Sensitivity Tests/methods ; Peptides, Cyclic/pharmacology ; Species Specificity
Keywords
Epigallocatechin 3-O-gallate ; Candida ; Susceptibility ; Antifungal agents
Abstract
This is the first report to investigate the antifungal susceptibility of 21 clinical isolates of seven Candida species to epigallocatechin 3-O-gallate (EGCg) and to compare with six antifungal agents, amphotericin B (AMPH), fluconazole (FLCZ), flucytosin (5FC), itraconazole (ITCZ), micafungin (MCFG), and miconazole (MCZ), using a method following the National Committee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Among the tested species, Candida glabrata exhibited the highest susceptibility to EGCg (MIC50, 0.5–1 μg/ml and MIC90, 1–2 μg/ml) compared favorably with FLCZ, although they were slightly less susceptible than to AMPH, 5FC, MCFG, ITCZ, and MCZ. Candida guilliemondii and Candida parapsilosis (MIC50, 1–4 μg/ml and MIC90, 2–16 μg/ml) were also susceptible to EGCg, although they appear to be slightly less susceptible to EGCg than C. glabrata and the other antifungal agents tested. Moreover, the susceptibility of Candida krusei strains (MIC50, 2 μg/ml and MIC90, 4–8 μg/ml) to EGCg was approximately 2- to 8-fold higher than those of 5FC and FLCZ. Our data indicate that EGCg can inhibit clinically pathogenic Candida species, although the concentrations of EGCg for antifungal susceptibility were slightly higher than those of tested antifungal agents on the whole. Based on these results, we suggest that EGCg may be effectively used as a possible agent or adjuvant for antifungal therapy in Candidiasis.
Full Text
http://www.sciencedirect.com/science/article/pii/S0006291X06013441
DOI
10.1016/j.bbrc.2006.06.037
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Medical Engineering (의학공학교실) > 1. Journal Papers
Yonsei Authors
Park, Jong Chul(박종철) ORCID logo https://orcid.org/0000-0003-0083-5991
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/110787
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse